XML 53 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814
Merger - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Jun. 15, 2015
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Business Acquisition [Line Items]          
Number of options, Granted       1,540,388  
Deferred tax liability   $ 2,959,000   $ 2,959,000  
In-process research and development   7,534,000   $ 7,534,000  
Effective tax rate       39.28%  
Operating losses   4,661,000 $ 2,594,000 $ 18,724,000 $ 7,453,000
Loss on conversion of convertible notes       $ (1,170,000)  
Restricted Stock Units [Member]          
Business Acquisition [Line Items]          
Restricted stock units, options vested       180,090  
2015 Bridge Notes [Member]          
Business Acquisition [Line Items]          
Common stock issued upon conversion of preferred stock and notes 664,559        
Loss on conversion of convertible notes $ (1,170,000) 0   $ (1,170,000)  
Pulmatrix Operating [Member]          
Business Acquisition [Line Items]          
Merger completion date Jun. 15, 2015        
Common stock exchange 0.1481871240        
Shares issued upon conversion of convertible preferred stock 70,105,854        
Debt instrument conversion, shares of common stock 86,118,402        
Pulmatrix Operating [Member] | Oculus Innovative Sciences Inc [Member]          
Business Acquisition [Line Items]          
Minimum sale price of acquired In-process research and development assets under license agreement $ 1,000,000        
Minimum sale price of acquired In-process research and development assets to be shared with related party $ 10,000,000        
Percentage of sales consideration of acquired In-process research and development assets payable to related party 10.00%        
Pulmatrix Operating [Member] | Common Stock [Member]          
Business Acquisition [Line Items]          
Common stock issued upon conversion of preferred stock and notes 4,155,539        
Pulmatrix Operating [Member] | Convertible Notes [Member]          
Business Acquisition [Line Items]          
Common stock issued upon conversion of preferred stock and notes 5,104,655        
Pulmatrix Operating [Member] | 2015 Bridge Notes [Member]          
Business Acquisition [Line Items]          
Common stock issued upon conversion of preferred stock and notes 664,559        
Business acquisition, principal amount of notes assumed $ 4,500,000        
Ruthigen [Member]          
Business Acquisition [Line Items]          
Merger agreement description       All Pulmatrix Operating stock options granted under the Pulmatrix Operating stock option plans (whether or not then exercisable) that were outstanding at the Effective Time converted into options to purchase Company Common Stock. After the Effective Time, all outstanding and unexercised Pulmatrix Operating stock options assumed by the Company may be exercised solely for shares of Company Common Stock. The number of shares of Company Common Stock subject to each Pulmatrix Operating stock option assumed by the Company was determined by multiplying (a) the number of shares of Pulmatrix Operating common stock that were subject to such Pulmatrix Operating stock option, as in effect immediately prior to the Effective Time, by (b) the Exchange Ratio, as defined in the merger agreement, and rounding the resulting number down to the nearest whole number of shares of Company Common Stock. The per share exercise price for the Company Common Stock issuable upon exercise of each Pulmatrix Operating stock option assumed by the Company was determined by dividing (a) the per share exercise price of Pulmatrix Operating common stock subject to such Pulmatrix Operating stock option, as in effect immediately prior to the Effective Time, by (b) the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent.  
Purchase price allocation description       The purchase price allocation has been prepared on a preliminary basis and is subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and the liabilities assumed. Any adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from June 15, 2015, the acquisition date.  
Adjustments to purchase price allocation period       No later than one year  
Goodwill description       Goodwill is calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. The goodwill is not expected to be deductible for income tax purposes. Goodwill is recorded as an indefinite-lived asset and is not amortized but tested for impairment on an annual basis or when indications of impairment exist.  
Deferred tax liability 2,959,000        
In-process research and development $ 7,534,000 7,534,000   $ 7,534,000  
Operating losses   108,000   1,373,000  
Transaction costs in connection with merger       6,863,000  
Transaction costs in connection with merger   $ 9,956,000   9,956,000  
Stock-based compensation expense related to acceleration of vesting       901,000  
Expenses related to stay bonuses       995,000  
Other expense related to change in fair value of liability classified       2,291,000  
Other income related to change in fair value of liability classified       1,309,000 1,275,000
Ruthigen [Member] | IPR&D [Member]          
Business Acquisition [Line Items]          
Discounted cash flow analysis rate 26.60%        
Ruthigen [Member] | Restricted Stock Units [Member]          
Business Acquisition [Line Items]          
Restricted stock units, options vested 130,435 49,655      
Ruthigen [Member] | 2015 Bridge Notes [Member]          
Business Acquisition [Line Items]          
Loss on conversion of convertible notes       1,170,000  
Interest expense       $ 477,000 $ 6,868,000
Ruthigen [Member] | 2013 Employee, Director and Consultant Equity Incentive Plan [Member]          
Business Acquisition [Line Items]          
Number of options, Granted 24,400        
Ruthigen [Member] | 2013 Employee, Director and Consultant Equity Incentive Plan [Member] | Restricted Stock Units [Member]          
Business Acquisition [Line Items]          
Restricted stock units, options vested 67,732